Novartis, a Swiss pharmaceutical company, is closely monitoring the proposed reciprocal tariffs by the U.S., as mentioned by Chief Executive Vas Narasimhan in Tokyo. President Donald Trump has highlighted the possibility of imposing import duties, including on pharmaceuticals, at around 25% to impact various industries like semiconductors and automobiles. Novartis is planning to commence large-scale production of radiopharmaceuticals in Japan by 2026, according to a report by the Nikkei newspaper. The company had acquired Mariana Oncology in the previous year for $1 billion to expand its drug portfolio, which features medications like Pluvicto for prostate cancer and Lutathera for rare gastrointestinal tumors.